COVID-19 vaccination poses no risk of serious adverse events to elderly, large study finds
By
Alicia Lasek
Nov 29, 2021
People aged 75 years and older have zero risk of serious adverse cardiovascular events after vaccination with the Pfizer-BioNTech COVID-19 vaccine, a new national study has found.
Clinical briefs for Thursday, Nov. 18
By
Alicia Lasek
Nov 18, 2021
OSHA suspends implementation of COVID-19 vaccine mandate for businesses … Feds expected to OK Pfizer’s COVID vaccine boosters for all adults; Moderna requests the same for its shot … 12 more...
Pfizer-BioNTech vaccine highly effective in octo- and nonagenarians, German study finds
By
Alicia Lasek
Nov 10, 2021
The data, from 700,000 older residents of Bavaria, resolves questions about the vaccine’s protectiveness that weren’t answered by the drugmaker’s clinical trials, investigators say.
COVID pill could prevent 9 in 10 hospitalizations, Pfizer says
By
Alicia Lasek
Nov 09, 2021
The antiviral Paxlovid reduced the rate of hospitalization and death from COVID-19 by nearly 90% in a clinical trial. A similar oral antiviral made by Merck currently is under review by the FDA.
Protection declines dramatically over time for all three COVID-19 vaccines: study
By
Amy Novotney
Nov 08, 2021
As the delta variant became the dominant strain of coronavirus across the United States, all three COVID-19 vaccines available to Americans lost some of their protective power, with vaccine efficacy among...
COVID-19 vaccine booster jab has 96 percent efficacy, Pfizer reveals
By
Alicia Lasek
Oct 22, 2021
A third dose of Pfizer-BioNTech’s vaccine restores protection against the disease to levels achieved after the second dose, a large new trial shows.
Federal health officials to OK mix-and-match booster vaccinations: report
By
Alicia Lasek
Oct 20, 2021
Clinicians will be free to administer any of the three U.S.-approved COVID-19 vaccines to eligible recipients once Moderna and Johnson & Johnson booster shots are authorized, sources say.
No unexpected pattern of adverse booster shot reactions reported by CDC app users
By
Alicia Lasek
Sep 30, 2021
Most v-safe app respondents reported mild to moderate, transient reactions, usually the day after vaccination, CDC investigators say. Sixty percent of respondents were between the ages of 50 and 74.
Booster clinics set to begin in facilities following CDC sign-off on Pfizer shot
By
Danielle Brown
Sep 27, 2021
Booster shot clinics at long-term care facilities are expected to begin immediately after the Centers for Disease Control and Prevention on Friday recommended that Pfizer’s COVID-19 booster dose be administered...
BREAKING: CDC recommends boosters for long-term care residents, workers
By
Danielle Brown
Sep 24, 2021
Pfizer’s COVID-19 booster shot will soon be administered to eligible long-term care residents and workers after the Centers for Disease Control and Prevention made a key recommendation early Friday.